Equities research analysts at HC Wainwright began coverage on shares of NeuroPace (NASDAQ:NPCE - Get Free Report) in a note issued to investors on Wednesday, Marketbeat reports. The firm set a "buy" rating and a $18.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 38.67% from the company's current price. HC Wainwright also issued estimates for NeuroPace's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.82) EPS and FY2026 earnings at ($0.57) EPS.
Other equities analysts have also recently issued reports about the company. Wells Fargo & Company lifted their price objective on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a report on Thursday, January 30th. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $17.00 price objective on shares of NeuroPace in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, NeuroPace presently has an average rating of "Moderate Buy" and a consensus price target of $15.50.
Check Out Our Latest Stock Report on NPCE
NeuroPace Price Performance
NASDAQ NPCE traded down $0.13 during midday trading on Wednesday, hitting $12.98. The company had a trading volume of 285,244 shares, compared to its average volume of 159,779. The company has a market capitalization of $425.73 million, a PE ratio of -12.98 and a beta of 2.04. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The firm has a 50-day moving average price of $12.82 and a 200-day moving average price of $12.12. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98.
NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. The firm had revenue of $22.52 million during the quarter, compared to analysts' expectations of $21.85 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. As a group, analysts anticipate that NeuroPace will post -1 earnings per share for the current fiscal year.
Insider Transactions at NeuroPace
In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares of the company's stock, valued at $51,325,454.15. This represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.20% of the stock is owned by insiders.
Hedge Funds Weigh In On NeuroPace
A number of institutional investors and hedge funds have recently bought and sold shares of NPCE. JPMorgan Chase & Co. increased its holdings in NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock worth $84,000 after purchasing an additional 6,181 shares in the last quarter. Financial Advocates Investment Management increased its holdings in NeuroPace by 27.8% in the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company's stock worth $257,000 after purchasing an additional 5,000 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in NeuroPace in the 4th quarter worth about $129,000. Bank of New York Mellon Corp increased its holdings in NeuroPace by 21.2% in the 4th quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock worth $328,000 after purchasing an additional 5,133 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in NeuroPace by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock worth $3,615,000 after purchasing an additional 5,781 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
